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ABSTRACT 
Sphingosine-1 phosphate (S1P) is involved in a variety of cellular processes via activation of 
S1P receptors (S1PRs; S1PR1 to S1PR5) that are highly expressed in the brain. It has been 
shown that the level of S1P is reduced in the brain of Alzheimer's disease (AD) patients. 
However, there is no study designed to evaluate the expression of S1PRs in AD brains. The 
objectives of the present work are (1) to examine the expression of S1PR1-3 in the hippocam-
pus of beta amyloid (Aβ) 1-42 injected rats and (2) to clarify the effects of chronic S1PR1 ac-
tivation on S1PR1-3 levels, spatial memory deficit and hippocampal damage in AD rats. 
SEW2871, the S1PR1 selective agonist, repeatedly was injected intraperitoneally during a pe-
riod of two weeks. Upon Western Blot data bilateral intrahippocampal injection of Aβ1-42 
decreased the expression of S1PR1 while increased S1PR2 level and did not affect that of 
S1PR3. We found that chronic administration of SEW2871 inhibited the reduction of S1PR1 
expression and ameliorated spatial memory impairment in the Morris water maze task in rats. 
In addition, SEW2871 attenuated the Aβ1-42-induced hippocampal neuronal loss according 
to Nissl staining findings. Data in the current study highlights the importance of S1PR1 sig-
naling pathway deregulation in AD development and suggests that activation of S1PR1 may 
represent a potential approach for developing new therapeutics to manage memory deficit and 
apoptosis associated with neurodegenerative disorders such as AD. 
 
Keywords: SEW2871, Cognitive function, Sphingosine-1 phosphate receptors, Alzheimer's 
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INTRODUCTION 
Sphingosine 1-phosphate (S1P) is a 
sphingolipid with important roles in and out 
of the cells. S1P regulates cell growth 
(Olivera and Spiegel, 1993) and suppresses 
the apoptosis (Cuvillier et al., 1996). The 
biological activities of S1P are mostly me-
diated by G-protein coupled receptors fami-
ly, termed as S1P receptors (S1PRs). 
Among S1PRs (S1PR1-5), S1PR1, S1PR2 
and S1PR3 are widely expressed in several 
tissues at various levels (Young and Van 
Brocklyn, 2006). Except S1PR4, all S1PR 
subtypes are expressed in the central nerv-
ous system (CNS) and S1PR1-3 levels are 
substantially high in the brain (MacLennan 
et al., 1994 ; Zhang et al., 1999). Among 
these, S1PR1 is highly expressed in white 
matter, hippocampus and the cerebellum 
(Chae et al., 2004) suggesting a critical role 
for S1PR1 in neural functions in these re-
gions. 
There is a confirmed connection be-
tween deregulation of S1P activity and 
some neurodegenerative diseases, neverthe-
less little is known about the relevance with 
Alzheimer's disease (AD). The S1PR1 has 
been shown to regulate lymphocytes egress 
from secondary lymphatic organs (Matlou-
bian et al., 2004) and to confer some bene-
ficial effects on ischemia conditions (Wei et 
al., 2010, Liesz et al., 2011). Thus some 
S1PR modulators like FTY720, have been 
approved as a first-line treatment for relaps-
ing remitting multiple sclerosis (Chiba et 
al., 2011). SEW2871, a selective agonist of 
S1PR1, also attenuates the expression of 
proinflammatory molecules and tissue inju-
ry under inflammatory conditions such as 
renal ischemia/reperfusion injury (Jo et al., 
2005, Awad et al., 2006, Lien et al., 2006), 
diabetic nephropathy and emphysema 
(Awad et al., 2006, Hofmann et al., 2009, 
Diab et al., 2010).  
AD is one of the neurodegenerative dis-
orders that is linked to neuro-inflammation 
and is characterized by progressive cogni-
tive decline and abnormalities in behavior. 
Accumulation of beta amyloid (Aβ) pep-
tides and neurofibrillary tangles are patho-
logical hallmarks of AD (Steinerman et al., 
2008; McNaull et al., 2009; Bhaskar and 
Lamb, 2012). Soluble Aβ oligomers acti-
vate sphingomyelinases, increase the level 
of ceramide (Obeid et al., 1993; Malaplate-
Armand et al., 2006) while AD patients 
brains shows reduced levels of the S1P 
(Brinkmann et al., 2010). Enhanced ratio of 
ceramids to S1P seems to be in favor of 
neuronal death in AD brains.  
According to the in vitro experiments, 
shifting the balance between S1P synthesiz-
ing (sphingosine kinases-1) and degrading 
(S1P-lyase or -phosphatase) enzymes to-
ward high levels of S1P (Van Veldhoven, 
2000; Le Stunff et al., 2002; Hla, 2003; 
Chae et al., 2004) is associated with de-
creased levels of ceramide and sphingosine 
and inhibits ceramide-induced apoptosis 
(Edsall et al., 2001; Reiss et al., 2004). 
S1PR1 activations seem to account for S1P 
anti-apoptotic effects (Cuvillier et al., 
1996). 
The present study aims to clarify the 
impact of S1PR1 signaling on AD progress 
and outcomes. According to some reports 
indicating that S1PRs expressions alter in 
some inflammatory conditions like renal 
ischemia-reperfusion injury (Awad et al., 
2006), we explored whether S1PRs levels 
changes in AD brain. Then the influence of 
chronic administration of SEW2871, the 
S1PR1 selective agonist, was evaluated on 
the corresponding S1PRs expressions, hip-
pocampal neuronal survival and on spatial 
learning and memory in Aβ1-42 injected 
rats. 
 
MATERIALS AND METHODS 
Drugs  
Aβ1-42 (Sigma-Aldrich, USA) stock 
solution was diluted by PBS to a concentra-
tion of 1 µg/µl and was incubated at 37 °C 
for 7 days to allow the formation of fibril 
aggregation. SEW2871 was purchased from 
Cayman Chemical and dissolved in Dime-
thyl sulfoxide (DMSO) to the final concen-
tration of 1 mg/ml.  
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 Animals and experimental groups 
The rats used in this study were males 
of the Wistar albino strain weighing 250–
300 g that were housed in cages (four per 
cage) with ad libitum food and water. The 
animals were maintained under a controlled 
environment (12 h light–dark cycle with 
lights on from 07:00 to 19:00 h and 25 ± 
2 °C room temperature). All animal manip-
ulations were carried out according to the 
Ethical Committee for the use and care of 
laboratory animals of Shahid Beheshti Uni-
versity of medical sciences in compliance 
with the standards of the European Com-
munities Council directive (86/609/EEC). 
Animals were randomly divided into 4 
groups as following (n=10 per each): 
(1) Control: the rats receiving intrahippo-
campal physiological buffer solution 
(PBS) (Aβ vehicle) injection and daily 
i.p. injection of DMSO (SEW2871 ve-
hicle) 
(2) SEW: the rats receiving intrahippocam-
pual PBS injection and daily i.p. injec-
tion of SEW2871 
(3) Aβ: the rats receiving intrahippocampal 
Aβ1-42 injection and daily i.p. injection 
of DMSO 
(4) Aβ+SEW: the rats receiving intrahippo-
campal Aβ1-42 injection and daily i.p. 
injection of SEW2871 
 
Drug administration 
The reagents used for AD induction or 
to stimulate S1PR1 in animals, were admin-
istered according to experimental schedule 
summarized in Figure 1. 
 
Aβ1-42 preparation and intrahippocampal 
injection 
Rats were anesthetized with chloral hy-
drate (400 mg/kg, i.p.) and placed in a ste-
reotaxic instrument (Stoelting, USA).  
The following coordinates were used 
for bilateral intrahippocampal injection: 
AP: -3.84 mm, L: ± 2.2 mm and V: 2.5 mm 
according to the atlas of rat brain (Paxinos 
and Watson, 2007). A solution containing 
2 µg aggregated Aβ1-42 or PBS (for con-
trol and SEW groups) of the same volume 
was injected. Solutions were administrated 
via Hamilton microsyringe. All injections 
were made at the rate of 2 μl/4min. To min-
imize leakage of the solutions, the needle 
was kept in the position for 2 min after in-
jection and the scalp was then closed with a 
suture. 
 
SEW2871 chronic treatment 
Started on the first day after the stereo-
taxic surgery, rats were injected with i.p. 
DMSO (the SEW2871 solvent) or 
SEW2871 (0.5 mg/kg) for 14 consecutive 
days (Park et al., 2010). At the end of drug 
treatment period (14th day after surgery) 
animals were sacrificed. 
 
Morris water maze test 
The behavioral studies were carried out 
on days 9-14 after the surgery. A circular 
water tank (140 cm diameter, 55 cm high) 
was divided into four equally spaced quad-
rants. A transparent platform was set at the 
southeast quadrant of the tank, 1 cm below 
the surface of the water. Extra-maze cues 
such as some racks, bookshelves, pictures 
on the walls, surrounded the room where 
the water maze was performed. On day 9th, 
rats were habituated to the pool by allowing 
them to perform a 120 s swimming without 
the platform. 
 
 
 
■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 
 
 
Figure 1: Diagrammatic representation of the 
study protocol. One day after the stereotaxic 
surgery, daily treatment with SEW2871 or vehi-
cle started, which continued for 14 days. Each 
small black square represents one day and the 
“gray mark” shows the time of the Morris water 
maze test performance. Scarification of animals 
was done 14 days after the surgery. 
Stereotaxic surgery 
Drug treatment 
14 days treatment 
Memory assessment 
Scarification of animals
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The task was conducted for four con-
secutive days. In each trial (that constitutes 
four trains), a rat was placed in the water at 
one of the four starting positions, with the 
sequence of the positions being selected 
randomly. The rat was allowed to swim un-
til it found the platform or till the 90 s had 
elapsed. In this latter case, the trial was 
terminated and the animal was put on the 
platform for 20 s. The distance moved (cm) 
and escape latency (s) to reach the platform 
was recorded by a computer.  
On day 14th, the platform was removed 
from the pool and animals underwent a 60 s 
spatial probe trial. The time spent (s) in the 
target quadrant that the platform was for-
merly located was recorded and compared 
between groups (Moradpour et al., 2006). 
 
Western blotting  
After behavioral tests, rats were sacri-
ficed and hippocampus (n=6) was used to 
determine the S1PR1-3 and cleaved caspa-
se-3 expression by Western blotting meth-
od. Hippocampal tissues were homogenized 
in ice-cold lysis buffer (50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 0.5 % Nonidet P-40, 
50 mM NaF, 20 mM EDTA, 1 mM sodium 
orthovanadate, 1 mM dithiothreitol, 0.1 % 
SDS, and 2 mM phenylmethylsulfonyl fluo-
ride). The homogeneate tissues were then 
centrifuged at 5,000 rpm for 10 min at 4 °C. 
The supernatants were collected as total 
protein extracts. Protein concentration was 
determined by using Bradford’s method 
(Bradford, 1976). Individual samples were 
subjected to SDS polyacrylamide gel elec-
trophoresis, and then transferred to polyvi-
nylidene fluoride membranes. Blotting 
membranes were incubated with nonfat 
milk and then incubated overnight at 4 °C 
with the primary antibodies against cleaved 
caspase-3 (Cell Signalling, Beverly, MA, 
USA; 1:1000), S1PR1 (Abcam, USA; 
1:1500), S1PR2 (Cayman Chemical, USA; 
1:1500), S1PR3 (Abcam, USA; 1:1500). 
Then the membranes were incubated with 
secondary antibodies and processed with 
enhanced chemiluminescence reagent kit 
(Amersham Biosciences Europe GmbH, 
Germany). The images were scanned and 
analyzed semiquantitatively in a blind fash-
ion using the Image J software. The expres-
sion of β-actin was used as an internal con-
trol for every experiment. 
 
Tissue processing and Nissl’s staining of 
hippocampus neurons 
After the behavioral assessment, 6 rats 
of experimental groups were anesthetized 
and sacrificed by decapitation. The brains 
of animals were removed and one hemi-
sphere was fixed in 4 % paraformaldehyde 
and embedded in paraffin. Serial coronal 
sections of 5 µm thickness were cut (begin-
ning from 2.7 mm posterior to Bregma 
through the hippocampus), a total of 9 sec-
tions were collected from each brain and 
Nissl’s staining was performed. Briefly, the 
sections were dipped into aqueous solution 
of cresyl violet (1 %) for 7 min and then 
washed with distilled water followed by 
placing in 95 % ethanol. The sections were 
then dehydrated in absolute alcohol, cleared 
and mounted with permount mounting me-
dium and analyzed under the light micro-
scope. The number of survived pyramidal 
cells was counted in a 1 mm length of CA1 
region of hippocampus under ×40 magnifi-
cation of light microscopy as performed 
previously (Xu et al., 2009) and the number 
of neurons in this region was counted in 
different groups and percentage of neuronal 
loss was compared. 
 
Statistical analysis 
All data were expressed as mean ± 
SEM. Data were analyzed by using one-
way ANOVA, followed by Tukey HSD 
post hoc analysis and P<0.05 was assumed 
to be statistically significant. All statistical 
studies were carried out with SPSS program 
(version 16.0, SPSS Inc., USA). 
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RESULTS 
Intrahippocampal injection of Aβ1-42 
modifies S1PR1,2 expressions 
In order to determine the effect of in-
trahippocampal injection of Aβ1-42 on 
S1PRs protein levels, the expressions of 
S1PR1-3 proteins (that are highly expressed 
in the brain) were evaluated by Western 
blotting method. Compared with control, 
the expression of S1PR1 was reduced 
prominently in rats hippocampus two weeks 
after Aβ1-42 (P<0.001) (Figure 2A), while 
the expression of S1PR2 was significantly 
elevated then (P<0.05) (Figure 2B) and no 
change was observed in S1PR3 expression 
(Figure 2C).  
 
SEW2871 chronic administration prevents 
the Aβ1-42-induced decrease in S1PR1 
level  
The expression of S1PR1-3 was also de-
termined in AD model rats chronically 
treated with SEW2871. According to the 
S1PR1-3 immunoblotting results, the ex-
pression of S1PR1 increased significantly 
in Aβ+SEW group compared with Aβ 
group (P<0.01) (Figure 2A). However, 
treatment with SEW2871 could not affect 
the S1PR2 and S1PR3 levels (Figure 2B, 
C). 
Regarding the positive influence of the 
SEW2871 on S1PR1 expression in Aβ1-42 
injected rats, we decided to examine the ef-
fects of chronic administration of SEW2871 
on cognitive deficit in AD model rats. 
 
SEW2871 improves memory performance 
of AD model rats in Morris water maze 
test 
In order to survey the spatial learning 
and memory performance in rats, the Mor-
ris water maze task was accomplished. Re-
sults showed that, comparing with control 
group, learning and memory ability of Aβ1-
42 injected rats were significantly impaired. 
The average escape latency in searching for 
the hidden underwater platform, decreased 
with the increase of training days. Injection 
of Aβ1-42 caused a significant decline in 
spatial learning as indicated by significant 
increases in distance moved and escape la-
tency (P<0.001) in searching for the under-
water platform (Figure 3A, B). In addition, 
the time spent in the target quadrant (in the 
probe test) decreased significantly 
(P<0.001) (Figure 3C). These results sho-
wed that the application of Aβ1-42 impai-
red rat’s spatial learning and memory. The 
effects of SEW2871 administration on spa-
tial learning and memory are shown in Fig-
ure 3. In the hidden platform test, admin-
istration of SEW2871 slightly improved the 
learning task in Aβ1-42 injected rats. The 
distance moved and escape latency to reach 
the hidden platform were slightly shorter in 
SEW2871-administrated AD model animals 
on 4th day of training, compared with rats 
were injected with Aβ1-42 only (P<0.05) 
(Figure 3A, B). In addition, after removing 
the platform, the time spent in the target 
quadrant increased significantly in Aβ in-
jected animals which received SEW2871 
compared with AD rats that did not receive 
the drug (P<0.05) (Figure 3C). 
Chronic administration of SEW2871 to 
PBS injected group resulted in no signifi-
cant change in learning task, but caused 
deficit in the memory performance. In 
probe test, the time spent in the target quad-
rant in PBS injected rats which chronically 
received SEW2871 was reduced signifi-
cantly, compared with control group 
(P<0.05) (Figure 3C). 
 
SEW2871 protects from apoptosis induced 
by Aβ1-42 exposure in CA1 region of  
hippocampus 
The results of microscopic examinations 
of the hippocampus sections showed that 
Aβ injection reduces neuronal layer thick-
ness in CA1 area of hippocampus and ad-
ministration of SEW2871 prevents the Aβ-
induced damage (Figure 4). Furthermore, 
intrahippocampal Aβ injection resulted in 
significant neural loss in CA1 area com-
pared with control animals (P<0.001) which 
was markedly attenuated by SEW2871 
treatment (P<0.05) (Table 1). 
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Figure 2: Effect of SEW2871 on S1PR1-3 expression in Aβ1-42 injected rats evaluated by Western 
blotting method. 15 days after the stereotaxic procedure, the expression of S1PR1-3 in hippocampus 
was detected. Results showed decreasing of S1PR1 (A) and increasing of S1PR2 (B) in AD model 
rats. Treatment of AD model rats with SEW2871 resulted in elevated levels of S1PR1 (A) in hippo-
campus and had no effect on S1P2 (B). The expression of S1P3 did not show any change between 
groups (C). β-actin protein was used here as an internal control. One representative Western blot is 
shown; n = 6. The band density values were calculated and the values from the control were used as 
1. Values are the mean ± S.E.M., **P<0.01 and ***P<0.001 vs. control group; ### P<0.001 vs. Aβ 
group. 
 
 
 
** 
***
β-actin 
45 KD 
45 KD 
45 KD 
β-actin  
β-actin  
S1PR1  43 KD
S1PR2 38 KD 
S1PR3 42 KD
A 
B 
Control          Aβ          Aβ+SEW 
Control          Aβ          Aβ+SEW 
Control          Aβ          Aβ+SEW 
C 
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Figure 3: Effect of SEW2871 on spatial learn-
ing and memory performance in Aβ1-42 inject-
ed rats in Morris water maze test. Intrahippo-
campal injection of PBS or Aβ1-42 (2 μg/2 μL/ 
rat hippocampus) was performed and from the 
next day, rats were treated with a daily intra-
peritoneal injection of SEW2871 (0.5 mg/kg) or 
DMSO (vehicle). Hidden platform test was car-
ried out on days 11-14 after the injection of 
Aβ1-42 and a probe trial was conducted in the 
day after the final training trial. Significant deficit 
in learning and memory performance was ob-
served in Aβ injected group and chronic treat-
ment with SEW2871 improved learning and 
memory task. Distance moved to reach platform 
(cm) (A) Escape latency in target quadrant 
(sec) (B) and Time spent in target quadrant 
(sec) (C) are shown and compared between the 
experimental groups. Data are expressed as 
mean ± S.E.M., n=10. *P<0.05, ***P<0.001 vs. 
control; #P<0.05, ###P<0.001 vs. Aβ group 
 
Table 1: Effect of chronically treatment of 
SEW2871 on Aβ1-42-induced neuronal loss in 
CA1 region of hippocampus 
Group 
Percentage of neuronal 
loss in CA1 area  
(mean ± SEM) 
Control 0 
Aβ 22.8 ± 1.2*** 
Aβ + SEW 10.20 ± 0.35# 
The number of surviving pyramidal cells in a 1-mm length of 
CA1 region of the hippocampus was counted at ×40 magni-
fication and the percentage of neuronal loss was calculated 
[(average neuron number in control group sections − num-
ber of neurons in treated group sections) / average neuron 
number in control group sections × 100]. Data shown as 
mean ± S.E.M., ***P < 0.001 vs. control group and # P < 
0.05 vs. Aβ group 
 
 
Figure 4: Effect of SEW2871 on Aβ-induced damage in CA1 region of rat hippocampus. Investigation 
of Nissl stained photomicrographs from CA1 region of hippocampus showed that the pyramidal cells 
layer in CA1 area of Aβ1-42-injected rats are markedly thinner than that in the control group. While in 
AD rats which chronically received SEW2871 it was as thick as that in control group. From left to right: 
control, Aβ, Aβ + SEW groups. Photos represent ×400 magnification 
A 
B 
C 
Aβ Control Aβ + SEW 
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Figure 5: Effect of SEW2871 on level of cleaved caspase-3 in the hippocampus of Aβ1-42 injected 
rats. The expression of cleaved caspase-3 was determined by Western blotting method. The level of 
cleaved caspase-3 in control, Aβ and Aβ + SEW groups (One representative Western blot is shown; 
n=6) (A). The relative densities of corresponding bands were measured and compared (B). Each point 
shows the mean ± S.E.M.,***P < 0.001 vs. control group and ## P< 0.01 vs. Aβ group 
 
 
To suggest about the apoptotic path-
ways, the intracellular levels of cleaved 
caspase-3 was measured to estimate caspa-
se-3 activation. The hippocampi Western 
blot analysis showed a significant increase 
in Aβ injected rats (P<0.001), while admin-
istration of SEW2871 in AD rats reduced 
the Aβ1-42 induced caspase-3 cleavage 
(p<0.05) (Figure 5). All together, these re-
sults suggest that both Aβ apoptotic effects 
and SEW2871 anti-apoptotic benefits may 
be mediated at least in part through caspa-
se-3 modifications.  
 
DISCUSSION 
Revealing the S1PRs signaling effects 
and interactions in the context of pathologi-
cal conditions may help to suggest new 
therapeutic approaches. Here we deter-
mined the changes occur in S1PRs levels in 
the hippocampus following exposure to 
Aβ1-42 fibrils. Then we pointed out that 
chronic administration of SEW2871 results 
in enhanced S1PR1 expression and reduced 
S1PR2 levels in AD model rats. SEW2871 
also attenuated Aβ-induced caspase-3 acti-
vation, hippocampal damage and cognitive 
impairment in AD animals. 
S1P decrease and ceramide increase in 
AD patient brains have been reported in 
some studies (He et al., 2010 ; de la Monte, 
2012). The apoptotic effects of Aβ are 
mimicked by ceramides (Liu et al., 1998; 
Yang et al., 2004). Although S1P may act 
as a non-competitive ceramide synthase in-
hibitor (Laviad et al., 2008) and inhibits the 
sphingomyelinase activity (Malaplate-Ar-
mand et al., 2006; Brinkmann et al., 2010), 
even low concentrations of ceramide cause 
cell death in mature hippocampal neurons 
(Mitoma et al., 1998). The S1P-ceramide 
imbalance could result in neuronal death 
and S1PRs agonists application could be 
introduced as a useful therapeutic approach 
to reduce Aβ-induced brain damages. 
As compared with other S1PRs, S1PR1 
is particularly abundant in hippocampus of 
rodents (Lee et al., 2010). It has been sug-
gested that the S1P exerts its anti-apoptotic 
effects mostly via S1PR1 activation (Young 
and Van Brocklyn, 2006). The present 
study indicates a significant decline in the 
S1PR1 level in AD model rats. Taken to-
gether, S1PR1 could be assumed as a po-
tential inhibitor of Aβ–induced cell death in 
hippocampus. To investigate this hypothe-
sis, the AD model rats were treated chroni-
cally with SEW2871.  
Upon our data, SEW2871 inhibited the 
Aβ-induced reduction in S1PR1 expression. 
This confirms some previous evidences in-
dicating that S1PR1 activation induces pro-
duction of growth factors and increases 
***
Cleaved  
Caspase-3  
β- actin  
17 KD
45 KD 
Control         Aβ         Aβ+SEW 
A  B
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S1PRs mRNA expression (Pitson et al., 
2005; Landeen et al., 2007). 
According to our histological studies 
along with cleaved caspase-3 immuno-blot-
ting results, SEW2871 inhibites the Aβ-in-
duced neural loss in CA1 region of hippo-
campus probably via attenuating caspase-3 
pathway. However the current results could 
not suggest about the underlying mecha-
nisms, these anti-apoptotic effects are in-
consistent with some studies examined 
S1PR1's protective role under inflammatory 
conditions like diabetic nephropathy and 
emphysema (Awad et al., 2006, Hofmann et 
al., 2009, Diab et al., 2010). S1PR1 signal-
ing has also been shown to be involved in 
stem/progenitor cells migration to damaged 
area of the CNS (Kimura et al., 2007) but it 
seems less likely to account for the im-
proved neural survival in just two weeks.  
The spatial memory deficit is an im-
portant hallmark of AD (Forsyth and 
Ritzline, 1998). This may be the probable 
consequence of events following Aβ accu-
mulation in pyramidal neurons, such as: 
glutamatergic synaptic transmission depres-
sion (Kamenetz et al., 2003), reduced glu-
tamate receptors (Almeida et al., 2005; Liu 
et al., 2010) and facilitation of the long-
term depression (LTD) of synaptic trans-
mission (Berdyshev et al., 2009). In the 
present work, we used Morris water maze 
to investigate cognitive abilities in animals 
and demonstrated that intrahippocampal 
injection of Aβ1-42 induced learning and 
memory deficit in animals as an important 
component of valid animal models of AD.  
S1P is involved in memory formation 
and glutamate release that seems to be part-
ly mediated by S1PR1 and S1PR3 
(Kajimoto et al., 2007). Long term potentia-
tion is impaired in sphingosine kinase-1 
(S1P synthesizing enzyme) knockout mice 
leading to spatial memory deficits (Kanno 
et al., 2010). In addition, S1PR1 induces Gi 
activation and cytoskeletal rearrangements 
through small G-protein Rac (Okamoto et 
al., 2000) which facilitates the transmitter 
secretion (Humeau et al., 2002) and may 
play a role in memory formation. Consist-
ently, data from the present work indicates 
that S1PR1 activation may prevent cogni-
tive deficit progress in AD. Upon our re-
sults, chronic administration of SEW2871, 
the selective agonist of S1PR1, improved 
the spatial learning and memory in animals 
after Aβ1-42. 
Some beneficial effects have also been 
demonstrated for S1PR3 activation in glu-
tamate transmission and cell survival 
(Brinkmann et al., 2010), nevertheless we 
did not observe any change in S1PR3 ex-
pression not in Aβ neither in Aβ+ 
SEW2871 animals as compared to control 
rats. 
However we did not use any specific 
S1PR2 agonist here, some previous reports 
have demonstrated that S1PR2 activation 
may induce apoptosis and necrosis in hu-
man proximal tubule cells (Park et al., 
2012) and neurite retraction (Toman and 
Spiegel, 2002). Cell rounding and neurite 
retraction has been observed in cultered 
hippocampal neurons exposed to Aβ aggre-
gates (Ivins et al., 1998). Upon our results 
S1PR2 expression increases in Aβ1-42 in-
jected hippocampi and is not affected with 
SEW2871 treatment in AD rats. In agree-
ment with this, enhanced levels of S1PR2 
mRNA expression previously have been 
identified in Aβ treated monocytes 
(Kaneider et al., 2004). Considering re-
duced S1P amounts in AD brains (He et al., 
2010) it seems probable that S1PR2 expres-
sion may be the result of compensatory 
mechanisms in the brain which may intensi-
fy neurodegeneration in the brain. 
Briefly the present study may suggest 
some significant interplay between S1PRs 
which may play a key role in AD progress. 
Our data confirms the importance of S1PR1 
signaling and emphasizes on the appropri-
ate agonists as potential new therapeutics 
for AD. However these experiments do not 
rule out the S1PR2 involvement. According 
to the enhanced S1PR2 levels in AD ani-
mals in this study, it is highly suggested to 
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evaluate the advantages of S1PR2 pharma-
cological blockage in animal models of AD.  
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